Icsm Screen Insulin Resistance Hypogonadism

---
name: icsm-screen-insulin-resistance-hypogonadism
description: This skill recommends screening men with obesity, type 2 diabetes mellitus, or metabolic syndrome for hypogonadism given the high comorbidity between these insulin‑resistant conditions and low testosterone. It is triggered when a clinician encounters a patient with obesity, diabetes, or metabolic syndrome and questions whether to check testosterone or suspects hypogonadism in this metabolic context.
---

# Screen for hypogonadism in insulin resistance conditions

## STEP 1 — Gather Information
Collect presence of obesity (BMI ≥30 kg/m² or waist circumference >102 cm), type 2 diabetes mellitus (known diagnosis or HbA1c ≥6.5 %), or metabolic syndrome (central obesity plus ≥2 of: raised triglycerides, reduced HDL‑C, elevated blood pressure, elevated fasting glucose). If any condition is present, proceed to Step 2; otherwise, do not screen for hypogonadism (universal screening not recommended).

## STEP 2 — Rule In / Rule Out
Is obesity, type 2 diabetes, or metabolic syndrome present?  
- **Yes** → Rule in: proceed to Step 3.  
- **No** → Rule out: stop; no testosterone screening indicated.

## STEP 3 — Classify or Stratify
Obtain a morning (07:00–11:00) fasting total testosterone (tT) using a reliable assay.  
- If tT ≥12 nmol/L (≥350 ng/dL) → Rule out hypogonadism; stop.  
- If tT <12 nmol/L (<350 ng/dL) → Proceed to Step 4 for confirmation.

## STEP 4 — Decide
Repeat tT on a separate occasion (morning, fasting).  
- If repeat tT <12 nmol/L (<350 ng/dL) → Diagnose hypogonadism; discuss testosterone therapy after shared decision‑making.  
- If repeat tT ≥12 nmol/L (≥350 ng/dL) → Rule out hypogonadism; stop.

## Clinical Guardrails / Mimics / Pitfalls
Do not perform universal screening in asymptomatic men without obesity, diabetes, or metabolic syndrome. Avoid testing during acute illness, as results may be transiently suppressed. In clear dysmetabolic states, consider measuring SHBG and albumin to calculate free testosterone if total testosterone is borderline. Do not rely solely on symptoms; biochemical confirmation on two occasions is required. Beware of overdiagnosis when using non‑fasting or non‑morning samples.

## Concrete Clinical Example
A 55‑year‑old man with BMI 32 kg/m², waist circumference 110 cm, and HbA1c 7.2 % presents for routine diabetes follow‑up; the clinician wonders whether to check testosterone. Step 1 identifies obesity and type 2 diabetes present. Step 2 rules in. Step 3 yields a morning tT of 10 nmol/L (<12 nmol/L). Step 4 repeats tT at 11 nmol/L (<12 nmol/L), confirming hypogonadism; testosterone therapy is discussed after shared decision‑making.

**Source:** Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024), International Society for Sexual Medicine, 2025, DOI: 10.1093/sxmrev/qeaf036